What are the next steps in management for an 85-year-old patient with known lung cancer who has a new adrenal mass?

Management of New Adrenal Mass in 85-Year-Old with Known Lung Cancer

In an 85-year-old patient with known lung cancer and a new adrenal mass, the immediate next step is to characterize the lesion using unenhanced CT with density measurements (threshold <10 HU indicates benign adenoma) or chemical shift MRI, followed by functional testing to exclude pheochromocytoma before any biopsy consideration.

Initial Imaging Characterization

The priority is determining whether this represents metastatic disease versus a benign incidental finding, as this fundamentally changes staging and treatment approach:

• Perform unenhanced CT with attenuation measurements 1, 2, 3

  • Lesions <10 Hounsfield Units (HU) are consistent with lipid-rich adenomas (benign)
  • Lesions >10 HU are indeterminate and require further evaluation
  • Important caveat: CT has limitations with ~21% of adenomas measuring >10 HU and ~11% of metastases measuring <10 HU 3

• Chemical shift MRI as alternative or confirmatory test 1, 2

  • Homogeneous signal intensity drop indicates lipid-rich adenoma
  • MRI shows 100% sensitivity for metastases but 50% false positive rate (misdiagnosing adenomas as metastases) 3
  • More cost-effective when used after indeterminate CT 2

Functional Testing - Critical Safety Step

Before any consideration of biopsy, you must exclude pheochromocytoma 1, 3. Screen for autonomous cortisol secretion as well, given that functional adenomas occur in 1-30% of adrenal incidentalomas 1.

Role of Biopsy

In the context of known lung cancer with an adrenal mass:

• CT-guided biopsy is necessary in most cases when imaging remains indeterminate 3, 4

  • Diagnostic certainty could not be obtained in 78% of patients despite extensive CT and MRI evaluation 3
  • Biopsy showed 100% sensitivity and specificity with no morbidity in surgical candidates 3
  • Critical: Only perform after excluding pheochromocytoma 1

• When biopsy is particularly indicated:

  • Indeterminate imaging findings (density 10-20 HU, heterogeneous MRI signal)
  • When confirming metastatic disease would change management decisions
  • In patients where surgical resection is being considered 1, 4

Prevalence Context

In patients with extra-adrenal malignancy, up to 70% of adrenal masses are metastatic 5. However, in isolated adrenal nodules without other metastatic disease, ~90% are benign 6. Lung cancer has particularly high rates of adrenal metastasis (32%) 6, making thorough characterization essential.

Predictive Factors for Metastasis

Higher likelihood of metastasis with 7, 6:

• SUVmax >3.05 on PET/CT (89% sensitivity, 69% specificity)
• Lesion size >14.5 mm (larger lesions 2-4 cm: OR 1.98; >4 cm: OR 3.25)
• Elevated CEA >4.45 ng/mL
• Presence of extra-adrenal metastatic disease (24.5% vs 10.8% metastasis rate)
• Advanced N stage (N3: OR 12.75)

Age-Specific Considerations

At 85 years old, treatment decisions should not be based solely on chronological age but on functional status, life expectancy, comorbidities, and patient preferences 8. However, this doesn't change the diagnostic workup—accurate staging remains essential for appropriate treatment selection.

Surgical Consideration (If Isolated Metastasis)

If imaging/biopsy confirms an isolated adrenal metastasis with no other sites of disease:

• Surgical resection can provide median survival of 14-24 months with ~30% achieving 5-year survival 9
• Laparoscopic adrenalectomy is feasible with 10.7% complication rate and no mortality in experienced hands 4
• Combined with immunotherapy, long-term survival >4 years has been reported for oligometastatic disease 10

Practical Algorithm

1. Unenhanced CT with density measurements (or chemical shift MRI if CT indeterminate)
2. Functional testing (exclude pheochromocytoma, screen for cortisol excess)
3. If lesion <10 HU and non-functional: Likely benign adenoma
   • If ≥4 cm: repeat imaging in 6-12 months 1
   • If <4 cm: no further follow-up needed 1
4. If lesion >10 HU or indeterminate: Proceed to CT-guided biopsy (after excluding pheochromocytoma)
5. If confirmed isolated metastasis in fit patient: Consider surgical resection
6. If multiple metastases or poor functional status: Systemic therapy per oncology

Common pitfall: Proceeding to biopsy without excluding pheochromocytoma can result in hypertensive crisis. Always perform functional testing first 1, 3.